Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells

Journal of Endocrinology

Volumn 195, Issue 1, 2007, Pages 125-131

  Krajisnik, Tijana ^a   Björklund, Peyman ^a   Marsell, Richard ^a   Ljunggren, Osten ^a   Åkerström, Göran ^a   Jonsson, Kenneth B ^a   Westin, Gunnar ^a   Larsson, Tobias E ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; MOLECULAR MARKER; OXYGENASE; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENCY; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONE INHIBITION; IN VITRO STUDY; NONHUMAN; PARATHYROID CELL; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; CATTLE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; DEPRESSION, CHEMICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTORS; FLOW CYTOMETRY; PARATHYROID GLANDS; PARATHYROID HORMONE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 35848947037     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/JOE-07-0267     Document Type: Article

References (39)

1. ADHR-Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics 26 345-348.
2. Bai X, Miao D, Li J, Goltzman D & Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145 5269-5279.
3. Benet-Pages A, Orlik P, Strom TM & Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Human Molecular Genetics 14 385-390.
4. Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS & Winer KK 2005 Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. Journal of Bone and Mineral Research 20 1944-1950.
5. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S et al. 2006 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nature Genetics 38 1310-1315.
6. Fukagawa M, Nakanishi S, Fujii H, Hamada Y & Abe T 2006 Regulation of parathyroid function in chronic kidney disease (CKD). Clinical and Experimental Nephrology 10 175-179.
7. Gupta A, Winer K, Econs MJ, Marx SJ & Collins MT 2004 FGF-23 is elevated by chronic hyperphosphatemia. Journal of Clinical Endocrinology and Metabolism 89 4489-4492.
8. Hoffman WH, Jueppner HW, Deyoung BR, O'Dorisio MS & Given KS 2005 Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. American Journal of Medical Genetics. Part A 134 233-236.
9. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T et al. 2004 FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney International 65 1943-1946.
10. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M & Miyamoto K 2005 Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. American Journal of Physiology and Endocrinological Metabolism 288 E1101-E1109.
11. Ito N, Fukumoto S, Taguchi M, Takeshita A, Takeuchi Y, Yamada S & Fujita T 2007 Fibroblast growth factor (FGF)23 in patients with acromegaly. Endocrine Journal 54 481-484.
12. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O et al. 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. New England Journal of Medicine 348 1656-1663.
13. Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S et al. 2005 Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney International 67 1120-1125.
14. Knutson A, Hellman P, Akerstrom G & Westin G 1998 Characterization of the human Megalin/LRP-2 promoter in vitro and in primary parathyroid cells. DNA and Cell Biology 17 551-560.
15. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW Moe OW et al. 2006 Regulation of fibroblast growth factor-23 signaling by klotho. Journal of Biological Chemistry 281 6120-6123.
16. Larsson T, Nisbeth U, Ljunggren O, Juppner H & Jonsson KB 2003a Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney International 64 2272-2279.
17. Larsson T, Zahradnik R, Lavigne J, Ljunggren O, Juppner H & Jonsson KB 2003b Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. European Journal Endocrinology 148 269-276.
18. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H & Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1 (I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145 3087-3094.
19. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ & White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. Journal of Clinical Endocrinology and Metabolism 90 2424-2427.
20. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE & Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. Journal of Biological Chemistry 278 37419-37426.
21. Livak KJ & Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(- ΔΔC(T)) method. Methods 25 402-408.
22. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH et al. 2006 DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nature Genetics 38 1248-1250.
23. Mirams M, Robinson BG, Mason RS & Nelson AE 2004 Bone as a source of FGF23: regulation by phosphate? Bone 35 1192-1199.
24. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T & Fukagawa M 2005 Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney International 67 1171-1178.
25. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A & Fukagawa M 2005 Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron. Clinical Practice 101 c94-c99.
26. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ et al. 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. Journal of Clinical Investigation 112 683-692.
27. Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerstrom G & Westin G 2002 25-Hydroxyvitamm D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. Journal of Clinical Endocrinology and Metabolism 87 2967-2972.
28. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F & Fukagawa M 2004 Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. American Journal of Kidney Diseases 44 250-256.
29. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. PNAS 98 6500-6505.
30. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143 3179-3182.
31. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K & Yamashita T 2004a Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. Journal of Clinical Investigation 113 561-568.
32. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T 2004b FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochemical and Biophysical Research Communication 314 409-414.
33. Shimada T, Hasegawa H, Yamazaki Y, Moto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S & Yamashita T 2004c FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research 19 429-435.
34. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H & Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biology 23 421-432.
35. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S & Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 770-774.
36. Westerberg PA, Linde T, Wikstrom B, Ljunggren O, Stridsberg M & Larsson TE 2007 Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrology, Dialysis, Transplantation (In Press).
37. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM & Econs MJ 2001a Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney International 60 2079-2086.
38. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O et al. 2001 b The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. Journal of Clinical Endocrinology and Metabolism 86 497-500.
39. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T et al. 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. Journal of Clinical Endocrinology and Metabolism 87 4957-4960.